- Home
- BIVI vs CLRB Comparison
BIVI vs CLRB Comparison
Compare BIVI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- CLRB
- Stock Information
- Founded
- BIVI 2013
- CLRB 2002
- Country
- BIVI United States
- CLRB United States
- Employees
- BIVI N/A
- CLRB N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- CLRB Health Care
- Exchange
- BIVI Nasdaq
- CLRB Nasdaq
- Market Cap
- BIVI 11.9M
- CLRB 14.2M
- IPO Year
- BIVI N/A
- CLRB N/A
- Fundamental
- Price
- BIVI $1.87
- CLRB $5.08
- Analyst Decision
- BIVI
- CLRB Hold
- Analyst Count
- BIVI 0
- CLRB 2
- Target Price
- BIVI N/A
- CLRB N/A
- AVG Volume (30 Days)
- BIVI 316.9K
- CLRB 127.5K
- Earning Date
- BIVI 11-12-2025
- CLRB 08-14-2025
- Dividend Yield
- BIVI N/A
- CLRB N/A
- EPS Growth
- BIVI N/A
- CLRB N/A
- EPS
- BIVI N/A
- CLRB N/A
- Revenue
- BIVI N/A
- CLRB N/A
- Revenue This Year
- BIVI N/A
- CLRB N/A
- Revenue Next Year
- BIVI N/A
- CLRB N/A
- P/E Ratio
- BIVI N/A
- CLRB N/A
- Revenue Growth
- BIVI N/A
- CLRB N/A
- 52 Week Low
- BIVI $1.42
- CLRB $4.11
- 52 Week High
- BIVI $75.00
- CLRB $67.50
- Technical
- Relative Strength Index (RSI)
- BIVI 33.55
- CLRB 52.18
- Support Level
- BIVI $1.54
- CLRB $4.82
- Resistance Level
- BIVI $1.68
- CLRB $5.34
- Average True Range (ATR)
- BIVI 0.14
- CLRB 0.37
- MACD
- BIVI 0.26
- CLRB 0.09
- Stochastic Oscillator
- BIVI 73.77
- CLRB 71.43
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.